drug · intermediate · partly written
CVnCoV (CureVac COVID-19 mRNA vaccine candidate)
CVnCoV was a chemically unmodified mRNA vaccine candidate that showed 48.2 percent efficacy in its phase 2b/3 trial and was never authorised.
Also called: CVnCoV
This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.
The short version
CVnCoV, an unmodified mRNA vaccine at 12 micrograms, was tested in 39,680 people across ten countries. It showed 48.2 percent efficacy against symptomatic disease (83 versus 145 cases). The company stopped its development and EMA ended its rolling review. 12
Reported, not yet replicated
The trial more
HERALD was a randomised, observer-blinded, placebo-controlled phase 2b/3 trial in 47 centres in ten countries of Europe and Latin America, NCT04652102. Participants received two 12-microgram doses on days 1 and 29, or saline. The primary endpoint was a first episode of virologically confirmed symptomatic COVID-19 from 15 days after the second dose, and success needed the lower confidence limit above 30 percent. There were 83 cases in the vaccine group and 145 in placebo: efficacy 48.2 percent (95.826 percent CI 31.0 to 61.4). Efficacy against moderate-to-severe disease was 70.7 percent and in ages 18 to 60 it was 52.5 percent; too few cases in people 61 or older to estimate. 1
Reported, not yet replicated
Why did it fall short more
Three explanations coexist and the trial cannot separate them. Variants: of 204 sequenced cases, 102 (50 percent) were variants of concern, and only about 3 percent were wild-type. Dose: the vaccine had 12 micrograms of mRNA against 30 micrograms for BNT162b2 and 100 micrograms for mRNA-1273, and the authors wrote they cannot dismiss that this dose was insufficient. Chemistry: it was chemically unmodified, and a review argues that the missing N1-methyl-pseudouridine explains the difference; that review states an argument, not a trial result. 13
Contested
Safety was not the reason more
Serious adverse events were reported by 0.4 percent of vaccine recipients and 0.3 percent of placebo recipients. Grade 3 solicited adverse events were reported by 27.1 percent versus 3.1 percent, so it was more reactogenic. 1
Reported, not yet replicated
What the regulators said deep
EMA ended its rolling review on 12 October 2021 after CureVac withdrew. EMA noted remaining questions about quality affecting benefit-risk and that the main study showed only modest efficacy in adults; the company said it was focusing on a different programme. The paper states the decision to cease CVnCoV activities was taken given variants and development timelines. 21
Reported, not yet replicated
Modality
Targets
Pathways
Indications
Identifiers
Trial
NCT04652102
Eudract
2020-003998-22
Platform
RNActive
Mechanism
Chemically unmodified mRNA encoding the stabilised full-length spike of the wild-type strain, protected by lipid nanoparticles and given intramuscularly; cells would make spike for the immune system to learn. 1
Reported, not yet replicated
Delivery route
Must survive
Side effects
Solicited reactions
Injection-site pain in 83.6 percent (1678 of 2007), fatigue in 80.0 percent and headache in 76.9 percent of vaccine recipients; grade 3 solicited events in 27.1 percent versus 3.1 percent with placebo. 1
Reported, not yet replicated
Serious adverse events
0.4 percent (82 of 19,783) of vaccine and 0.3 percent (66 of 19,746) of placebo recipients; none of the fatal events was judged related to vaccination. 1
Reported, not yet replicated
Verdict
Outcome
failed
Failure mode
Efficacy against symptomatic disease was 48.2 percent (83 versus 145 cases), with half of sequenced cases variants of concern. The authors say the 12 microgram dose may have been insufficient; a review argues the missing nucleoside modification; the trial cannot separate them. The company ceased CVnCoV activities and EMA ended its rolling review. 123
Contested
Teach this
In one sentence
CVnCoV was an unmodified mRNA vaccine at a lower dose that achieved 48.2 percent efficacy in a variant-heavy trial and was abandoned. 123
Reported, not yet replicated
The five-minute version
CureVac tested a 12-microgram unmodified mRNA vaccine in lipid particles in 39,680 people. Cases were 83 on vaccine versus 145 on placebo, an efficacy of 48.2 percent, well below the 95 percent in the Comirnaty trial. Half of sequenced cases were variants of concern, the dose was lower, and the RNA was unmodified, and no one trial can say which mattered. EMA ended its review after the company withdrew. 123
Reported, not yet replicated
What a listener will ask
Was it unsafe?
Is unmodified RNA the proven cause?
No. The trial did not vary chemistry. A review argues for it.
Can we compare 48 percent to 95 percent?
Not directly: dose, period, variants, case definition and age mix all differ.
The common wrong idea
CVnCoV failed because its RNA was unmodified.
That is plausible, but the trial changed dose and era at the same time and cannot isolate the RNA chemistry; the authors name variants and dose themselves.
The one citation to hand over: 1
Still open here
- What caused the lower efficacy? Variants, a 12 microgram dose and unmodified RNA all differ from Comirnaty and the trial did not isolate any of them.
- Is the unmodified RNA the main cause? A review argues so; no head-to-head test was found.
- No company product code was opened; only NCT04652102 and EudraCT 2020-003998-22 were read.
Not yet written: Assays used, Off targets.
Linked from
Sources
- Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, et al.. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis 22:329-340 (2022). paper; opened 2026-11-17 all records citing this
- European Medicines Agency. EMA ends rolling review of CVnCoV COVID-19 vaccine following withdrawal by CureVac AG. EMA news page, 12 October 2021 (2021). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- Morais P, Adachi H, Yu YT. The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines. Front Cell Dev Biol 9:789427 (2021). review; opened 2026-11-17 all records citing this
History of this record (5)
This record has been changed 5 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Year
- 2021
- Regulatory status
- failed-in-trials
- Status
- partly written
- Last updated
- 2026-11-19
- Record
- content/drugs/cvncov.json